Anti-Inflammatory and Profibrinolytic Effect of Insulin in Acute ST-Segment-Elevation Myocardial Infarction

Circulation

Volumn 109, Issue 7, 2004, Pages 849-854

  Chaudhuri, Ajay ^a   Janicke, David ^b   Wilson, Michael F ^a   Tripathy, Devjit ^a   Garg, Rajesh ^a   Bandyopadhyay, Arindam ^a   Calieri, Janeen ^c   Hoffmeyer, Debbie ^a   Syed, Tufail ^a   Ghanim, Husam ^a   Aljada, Ahmad ^a   Dandona, Paresh ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c GATES VASCULAR INSTITUTE AT KALEIDA HEALTH   (United States)

Author keywords

Atherosclerosis; Inflammation; Insulin; Myocardial infarction

Indexed keywords

ACETYLSALICYLIC ACID; CHOLESTEROL; CREATINE KINASE; CREATINE KINASE MB; FIBRINOLYTIC AGENT; GLUCOSE INSULIN POTASSIUM; HEMOGLOBIN A1C; HEPARIN; HUMAN INSULIN; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METOPROLOL; PLASMINOGEN ACTIVATOR INHIBITOR 1; RETEPLASE; SERUM AMYLOID A; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROSCLEROSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DIABETES MELLITUS; FEMALE; HEART INFARCTION; HUMAN; INFLAMMATION; INSULIN INFUSION; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOOD GLUCOSE; C-REACTIVE PROTEIN; COMORBIDITY; CREATINE KINASE; CREATINE KINASE, MB FORM; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INFLAMMATION; INSULIN; ISOENZYMES; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NADPH OXIDASE; PHOSPHOPROTEINS; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECOMBINANT PROTEINS; SERUM AMYLOID A PROTEIN; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 10744232591     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000116762.77804.FC     Document Type: Article

References (31)

1. Diaz R, Paolasso EA, Piegas LS, et al. Metabolic modulation of acute myocardial infarction. The ECLA (Estudios Cardiologicos Latino-america) Collaborative Group. Circulation. 1998;98:2227-2234.
2. Malmberg K, Ryden L, Efendic S, et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol. 1995;26:57-65.
3. van der Horst I, Zijlstra F, van't Hof A, et al. Glucose-insulin-potassium infusion in patients treated with primary angioplasty for acute myocardial infarction. J Am Coll Cardiol. 2003;42:784-791.
4. Jonassen AK, Sack MN, Mjos OD, et al. Myocardial protection by insulin at reperfusion requires early administration and is mediated via Akt and p70s6 kinase cell-survival signaling. Circ Res. 2001;89:1191-1198.
5. Apstein CS, Taegtmeyer H. Glucose-insulin-potassium in acute myocardial infarction: the time has come for a large, prospective trial. Circulation. 1997;96:1074-1077.
6. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999; 340:115-126.
7. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135-1143.
8. Aljada A, Ghanim H, Saadeh R, et al. Insulin inhibits NFkappaB and MCP-1 expression in human aortic endothelial cells. J Clin Endocrinol Metab. 2001;86:450-453.
9. Dandona P, Aljada A, Mohanty P, et al. Insulin inhibits intranuclear NFkB and stimulates IkB in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect? J Clin Endocrinol Metab. 2001;86:3257-3265.
10. Ryan TJ, Antman EM, Brooks NH, et al. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/Ameiican Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol. 1999; 34:890-911.
11. Aljada A, Ghanim H, Mohanty P, et al. Insulin inhibits the proinflammatory transcription factor early growth response gene-1 (Egr)-1 expression in mononuclear cells (MNC) and reduces plasma tissue factor (TF) and plasminogen activator inhibitor-1 (PAI-1) concentrations. J Clin Endocrinol Metab. 2002;87:1419-1422.
12. Lincoff AM, Kereiakes DJ, Mascelli MA, et al. Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization. Circulation. 2001;104:163-167.
13. Andreotti F, Hackett DR, Haider AW, et al. Von Willebrand factor, plasminogen activator inhibitor-1 and C-reactive protein are markers of thrombolytic efficacy in acute myocardial infarction. Thromb Haemost. 1992;68:678-682.
14. Pietila K, Harmoinen A, Hermens W, et al. Serum C-reactive protein and infarct size in myocardial infarct patients with a closed versus an open infarct-related coronary artery after thrombolytic therapy. Eur Heart J. 1993;14:915-919.
15. Anzai T, Yoshikawa T, Shiraki H, et al. C-reactive protein as a predictor of infarct expansion and cardiac rupture after a first Q-wave acute myocardial infarction. Circulation. 1997;96:778-784.
16. Pietila KO, Harmoinen AP, Jokiniitty J, et al. Serum C-reactive protein concentration in acute myocardial infarction and its relationship to mortality during 24 months of follow-up in patients under thrombolytic treatment. Eur Heart J. 1996;17:1345-1349.
17. Anzai T, Yoshikawa T, Takahashi T, et al. Early use of beta-blockers is associated with attenuation of serum C-reactive protein elevation and favorable short-term prognosis after acute myocardial infarction. Cardiology. 2003;99:47-53.
18. de Lemos JA, Antman EM, Gibson CM, et al. Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction: observations from the TIMI 14 trial. Circulation. 2000;101: 239-243.
19. Griselli M, Herbert J, Hutchinson WL, et al. C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J Exp Med. 1999;190:1733-1740.
20. Liuzzo G, Biasucci LM, Gallimore JR, et al. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med. 1994;331:417-424.
21. Genser N, Lechleitner P, Maier J, et al. Rebound increase of plasminogen activator inhibitor type I after cessation of thrombolytic treatment for acute myocardial infarction is independent of type of plasminogen activator used. Clin Chem. 1998;44:209-214.
22. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med. 1993;329:1615-1622.
23. Collet JP, Montalescot G, Vicaut E, et al. Acute release of plasminogen activator inhibitor-1 in ST-segment elevation myocardial infarction predicts mortality. Circulation. 2003;108:391-394.
24. Vaughan DE, Declerck PJ, Van Houtte E, et al. Reactivated recombinant plasminogen activator inhibitor-1 (rPAI-1) effectively prevents thrombolysis in vivo. Thromb Haemost. 1992;68:60-63.
25. Collard CD, Gelman S. Pathophysiology, clinical manifestations, and prevention of ischemia-reperfusion injury. Anesthesiology. 2001;94: 1133-1138.
26. de Lemos JA, Braunwald E. ST segment resolution as a tool for assessing the efficacy of reperfusion therapy. J Am Coll Cardiol. 2001;38: 1283-1294.
27. Grover A, Padginton C, Wilson MF, et al. Insulin attenuates norepinephrine-induced venoconstriction: an ultrasonographic study. Hypertension. 25(4 pt 2):779-784, 1995.
28. Steinberg HO, Brechtel G, Johnson A, et al. Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent: a novel action of insulin to increase nitric oxide release. J Clin Invest. 1994;94:1172-1179.
29. Trovati M, Massucco P, Mattiello L, et al. Insulin increases guanosine-3′,5′-cyclic monophosphate in human platelets: a mechanism involved in the insulin anti-aggregating effect. Diabetes. 1994;43:1015-1019.
30. Shamir R, Shehadeh N, Rosenblat M, et al. Oral insulin supplementation attenuates atherosclerosis progression in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2003;23:104-110.
31. Van Den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. N Engl J Med. 2001;345:1359-1367.